Publications
BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.
Note: Some Publications were unable to be listed below - please see that listing here. All other publications based on PubMedIDs are listed below.
Found 139 results
“Are We Making PROGRESS in Preventing Graft-versus-Host Disease and Improving Clinical Outcomes? Impact of BMT CTN 1301 Study Results on Clinical Practice.”, Transplant Cell Ther, vol. 28, no. 8, pp. 419-425, 2022.
, “Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial.”, Lancet Haematol, 2022.
, “Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012.”, Transplant Cell Ther, vol. 28, no. 7, pp. 406.e1-406.e6, 2022.
, “The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials.”, Transplant Cell Ther, 2022.
, “Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD.”, Bone Marrow Transplant, vol. 57, no. 2, pp. 302-303, 2022.
, “Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT).”, Blood Cancer J, vol. 12, no. 2, p. 27, 2022.
, “A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial.”, Transplant Cell Ther, 2022.
, “Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.”, Transplant Cell Ther, vol. 28, no. 8, pp. 446-454, 2022.
, “Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.”, J Clin Oncol, vol. 40, no. 4, pp. 356-368, 2022.
, “Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma.”, Am J Hematol, 2022.
, “Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.”, N Engl J Med, vol. 387, no. 2, pp. 132-147, 2022.
, “Two-sample survival probability curves: A graphical approach for the analysis of time to event data in clinical trials.”, Contemp Clin Trials, vol. 115, p. 106707, 2022.
, “Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes.”, Transplant Cell Ther, vol. 28, no. 2, pp. 109.e1-109.e8, 2022.
, “The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.”, Transplant Cell Ther, vol. 27, no. 10, pp. 807-816, 2021.
, “Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study.”, J Clin Oncol, vol. 39, no. 17, pp. 1878-1887, 2021.
, “Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.”, J Clin Oncol, vol. 39, no. 30, pp. 3328-3339, 2021.
, “Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.”, Transplant Cell Ther, vol. 27, no. 11, pp. 885-907, 2021.
, “Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: Challenges and opportunities in implementation.”, Cancer, vol. 127, no. 23, pp. 4339-4347, 2021.
, “Building a Fit for Purpose Clinical Trials Infrastructure to Accelerate the Assessment of Novel Hematopoietic Cell Transplantation Strategies and Cellular Immunotherapies.”, J Clin Oncol, vol. 39, no. 5, pp. 534-544, 2021.
, “Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial.”, Blood, vol. 137, no. 3, pp. 420-428, 2021.
, “Engraftment of Double Cord Blood Transplantation after Nonmyeloablative Conditioning with Escalated Total Body Irradiation Dosing to Facilitate Engraftment in Immunocompetent Patients.”, Transplant Cell Ther, vol. 27, no. 10, pp. 879.e1-879.e3, 2021.
, “Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023.”, Transplant Cell Ther, vol. 27, no. 2, pp. 183.e1-183.e7, 2021.
, “Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial.”, Front Immunol, vol. 12, p. 700045, 2021.
, “Impact of Changes of the 2020 Consensus Definitions of Invasive Aspergillosis on Clinical Trial Design: Unintended Consequences for Prevention Trials?”, Open Forum Infect Dis, vol. 8, no. 10, p. ofab441, 2021.
, ,